Journal article
Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC).
- Stinchcombe, Tom Duke University, Durham, NC;
- Stahel, Rolf A. University Hospital Zurich, Clinic of Oncology, Zurich, Switzerland;
- Bubendorf, Lukas University Hospital Basel, Institute of Pathology, Basel, Switzerland;
- Bonomi, Philip Rush University Medical Center, Chicago, IL;
- Villegas, Augusto E. Cancer Specialists of North Florida, Jacksonville, FL;
- Kowalski, Dariusz Maria Skłodowska-Curie Memorial Cancer Center, Warsaw, Poland;
- Baik, Christina S. University of Washington, Seattle, WA;
- Isla, Dolores Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain;
- De Castro, Javier Hospital Universitario La Paz, Madrid, Spain;
- Garrido Lopez, Pilar Hospital Ramón y Cajal, Madrid, Spain;
- Rittmeyer, Achim Fachklinik für Lungenerkrankungen, Immenhausen, Germany;
- Tiseo, Marcello Medical Oncology Unit, University Hospital of Parma, Parma, Italy;
- Stanzel, Sven Franz F. Hoffmann-La Roche Ltd., Basel, Switzerland;
- de Haas, Sanne F. Hoffmann-La Roche Ltd., Basel, Switzerland;
- Lam, Lisa Genentech, Inc., San Francisco, CA;
- Lu, Michael Genentech, Inc., San Francisco, CA;
- Peters, Solange Lausanne University Hospital, Lausanne, Switzerland;
Published in:
- Journal of Clinical Oncology. - American Society of Clinical Oncology (ASCO). - 2017, vol. 35, no. 15_suppl, p. 8509-8509
English
8509 Background: T-DM1 is an antibody-drug conjugate approved for HER2-positive metastatic breast cancer. We report primary results from a fully enrolled, ongoing phase 2 study (NCT02289833) of pts with previously treated HER2-overexpressing mNSCLC who received single-agent T-DM1. Methods: Eligible pts had HER2-overexpressing mNSCLC and were previously treated with platinum-based therapy. Pts received T-DM1 3.6 mg/kg every 3 weeks and were analyzed in 2 cohorts based on centrally determined HER2 status (immunohistochemistry [IHC]2+ vs IHC3+ [≥10% cells stained with 2+ or 3+ intensity, respectively]). HER2 amplification was assessed via ISH (HER2 gene ratio ≥2.0). The primary endpoint is objective response rate (ORR; proportion of pts with confirmed [≥4 weeks] complete or partial response per RECIST v1.1). Results: The clinical cutoff date for this analysis was Oct 26, 2016.Of 393 screened pts, 102 (27%) were IHC2+ and 29 (7%) were IHC3+. In total, 49 pts (IHC2+, n = 29; IHC3+, n = 20) received T-DM1. At cutoff, median follow-up was 16.3 (range 0.9*–22.4; * = censored observation) months. No IHC2+ pt had a response (0%, 95% CI 0–11.9); 4 IHC3+ pts had partial responses (20%, 95% CI 5.7–43.7) with a median duration of response of 7.3 (range 2.9–8.3) months. Median progression-free survival (PFS) in IHC2+ and IHC3+ pts was 2.6 (95% CI 1.4–2.8) and 2.7 (95% CI 1.4–8.3) months, respectively. At 6 months after start of study treatment, 9 pts (IHC2+, n = 4; IHC3+, n = 5) were still at risk for a PFS event. Median overall survival was 12.2 (95% CI 3.8–not estimable [NE]) months in IHC2+ pts and 12.1 (95% CI 9.3–NE) months in IHC3+ pts. Of 16 pts with HER2 amplification (IHC2+, n = 5; IHC3+, n = 11), 3 responded, all in the IHC3+ cohort (27.3%, 95% CI 6.0–61.0). Eleven pts (22%) experienced a grade 3–4 adverse event, with fatigue and dyspnea being the only events reported in > 1 pt (n = 2 each). Conclusions: This is the first study to report on the clinical activity of T-DM1 in HER2-overexpressing mNSCLC. Objective responses were observed in IHC3+ pts. Additional molecular analyses are underway to refine markers for optimal pt selection. Clinical trial information: NCT02289833.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1200/jco.2017.35.15_suppl.8509
- ISSN 0732-183X
- Persistent URL
- https://folia.unifr.ch/global/documents/244306
Statistics
Document views: 56
File downloads: